AstraZeneca Pharma India Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)Regulation, 2015'.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 1.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and market Durvalumab Solution for Infusion (Brand: Imfinzi, 120 mg/2.4 ml and 500 mg/10 ml) in India for an additional indication. The new approval covers first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, using Durvalumab in combination with carboplatin and paclitaxel, followed by maintenance with Durvalumab plus olaparib for mismatch repair proficient (pMMR) endometrial cancer. The company will now be able to market Imfinzi in India for this new use, subject to any further statutory approvals. This expands the therapeutic scope of an already approved oncology product in the Indian market.
This is a positive development for AstraZeneca Pharma India as it broadens the addressable patient base for Imfinzi in India, potentially driving incremental revenue from the oncology segment. The stock may see a mildly positive reaction, though the contribution depends on the size of the eligible endometrial cancer patient pool and pricing dynamics in India.